| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Malignant glioma is the most common malignant primary brain tumor, and despite recent progress in multimodarity treatment, the prognosis of the patients remains very poor. Oncolytic viral (OV) therapy has been considered as a promising treatment modality for malignant glioma. We investigated OV therapy-induced changes in the tumor microenvironment and the combination therapy of OV & antiangiogenic drug for malignant glioma. We revealed the mechanism of this combination therapy. Our results provide us a rationale for designing future clinical trials combining the two agents.
|
